Cargando…

A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example

BACKGROUND: Assessment of the clinical significance of unclassified variants (UVs) identified in BRCA1 and BRCA2 is very important for genetic counselling. The analysis of co-segregation of the variant with the disease in families is a powerful tool for the classification of these variants. Statisti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohammadi, Leila, Vreeswijk, Maaike P, Oldenburg, Rogier, van den Ouweland, Ans, Oosterwijk, Jan C, van der Hout, Annemarie H, Hoogerbrugge, Nicoline, Ligtenberg, Marjolijn, Ausems, Margreet G, van der Luijt, Rob B, Dommering, Charlotte J, Gille, Johan J, Verhoef, Senno, Hogervorst, Frans B, van Os, Theo A, Gómez García, Encarna, Blok, Marinus J, Wijnen, Juul T, Helmer, Quinta, Devilee, Peter, van Asperen, Christi J, van Houwelingen, Hans C
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714556/ https://www.ncbi.nlm.nih.gov/pubmed/19563646 http://dx.doi.org/10.1186/1471-2407-9-211

Ejemplares similares

A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history
por: Gómez García, Encarna B, et al.
Publicado: (2009)

Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of ‘easy to apply’ probability models
por: Bodmer, D, et al.
Publicado: (2006)

Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2
por: Oldenburg, RA, et al.
Publicado: (2005)

HIF-1α Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers
por: van der Groep, Petra, et al.
Publicado: (2013)

Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas
por: Weren, Robbert D.A., et al.
Publicado: (2016)

Finding all BRCA pathogenic mutation carriers: best practice models
por: Hoogerbrugge, Nicoline, et al.
Publicado: (2016)

DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct
por: Sie, Aisha S, et al.
Publicado: (2012)

Exome Sequencing of Germline DNA from Non-BRCA1/2 Familial Breast Cancer Cases Selected on the Basis of aCGH Tumor Profiling
por: Hilbers, Florentine S., et al.
Publicado: (2013)

Attitude towards pre-implantation genetic diagnosis for hereditary cancer
por: Lammens, Chantal, et al.
Publicado: (2009)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling
por: Sie, Aisha S., et al.
Publicado: (2015)

Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers
por: Derks-Smeets, Inge A. P., et al.
Publicado: (2018)

Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study
por: de Jonge, Marthe M, et al.
Publicado: (2021)

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2019)

Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy
por: Schmidt, MK, et al.
Publicado: (2005)

Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial
por: Visser, Annemiek, et al.
Publicado: (2011)

The functional impact of variants of uncertain significance in BRCA2
por: Mesman, Romy L. S., et al.
Publicado: (2018)

Clustering of known low and moderate risk alleles rather than a novel recessive high‐risk gene in non‐BRCA1/2 sib trios affected with breast cancer
por: Hilbers, Florentine S., et al.
Publicado: (2020)

Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences
por: Velthuizen, Mary E., et al.
Publicado: (2021)

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study
por: Akdeniz, Delal, et al.
Publicado: (2021)

BRCA1 and BRCA2 Unclassified Variants and Missense Polymorphisms in Algerian Breast/Ovarian Cancer Families
por: Cherbal, Farid, et al.
Publicado: (2012)

Familial gastric cancer: detection of a hereditary cause helps to understand its etiology
por: Vogelaar, Ingrid P, et al.
Publicado: (2012)

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
por: van Sprundel, T C, et al.
Publicado: (2005)

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition
por: Vos, Janet R, et al.
Publicado: (2019)

Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants
por: Vallée, Maxime P., et al.
Publicado: (2016)

Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies
por: Gonzalez-Neira, Anna, et al.
Publicado: (2007)

Clinically Significant Unclassified Variants in BRCA1 and BRCA2 genes among Korean Breast Cancer Patients
por: Yoon, Kyong-Ah, et al.
Publicado: (2017)

Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation
por: van Roosmalen, M S, et al.
Publicado: (2004)

Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2
por: Mesman, Romy L. S., et al.
Publicado: (2020)

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
por: Osorio, A, et al.
Publicado: (2011)

DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer
por: Flower, Kirsty J, et al.
Publicado: (2016)

Response to Tomao, Panici, and Tomao
por: Vos, Janet R, et al.
Publicado: (2019)

Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer
por: Cao, Wen-Ming, et al.
Publicado: (2016)

miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers
por: Vos, Shoko, et al.
Publicado: (2015)

Correction: Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2
por: Mesman, Romy L. S., et al.
Publicado: (2020)

Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients
por: Lee, Eunjung, et al.
Publicado: (2008)

Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls
por: van Voss, Marise R Heerma, et al.
Publicado: (2010)

Uptake of prenatal diagnostic testing for retinoblastoma compared to other hereditary cancer syndromes in the Netherlands
por: Dommering, Charlotte J., et al.
Publicado: (2016)

Germline MUTYH gene mutations are not frequently found in unselected patients with papillary breast carcinoma
por: Boesaard, Ewout P, et al.
Publicado: (2014)

The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era - historical perspectives
por: van de Vijver, Marc J
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_p4rbim21l4rmlr3q60tle6ue6a